Longeveron Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Longeveron Inc in the second quarter 2026?
Longeveron Inc recorded a cumulative net loss of $-23 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -223.19%.

Within the Major Pharmaceutical Preparations industry 325 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3072 to 3771.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-17.81 %	-6.59 %	-74.07 %	-61.11 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-23	-22	-23	-21	-19
Return On Equity (TTM)	-223.19 %	-202.41 %	-199.79 %	-138.44 %	-96.68 %
LGVN's Total Ranking	# 3771	# 3072	# 3328	# 3207	# 2812
Equity (TTM) in Millions	10	16	6	10	13
Seq. Equity Change	-35.1 %	182.41 %	-43.06 %	-21.25 %	-26.24 %
Seq. Net Income Change	-	-	-	-	-

Back to LGVN Management Effectiveness >> LGVN's 5 Years Annual ROE >> Compare LGVN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 326
Sector	# 685
Overall	# 3771

Return On Equity Statistics
High	Average	Low
-58.5 %	-152.23 %	-356.32 %
(Jun 30 2022)		(Jun 30 2024)

News about Longeveron Inc Return on Equity ROE

Navigating the Regulatory Landscape Longeverons Lomecel-B and the Future of Rare Pediatric Cardiac Disease Treatment

The intersection of healthcare innovation and regulatory frameworks is a pivotal area in the pharmaceutical sciences, especially for diseases that are rare and challenging to treat, such as Hyoplastic Left Heart Syndrome (HLHS). Longeveron, a clinical-stage biotechnology company, stands at the forefront of this narrative with its investigational product, Lomecel-B. Recent announcements from Longeveron regarding their positive engagement with the U.S. Food and Drug Administration (FDA) and the completion of an investigator meeting for their Phase 2b clinical trial underscore significant progress in the pathway toward potential approval and therapeutic application of Lomecel-B. Understanding Hypoplastic Left Heart Syndrome (HLHS)HLHS is a congenital heart defect characterized by the underdevelopment of the left side of the heart. This condition presents considerable challenges in management and treatment, typically necessitating a series of surgeries or heart transplant in the most severe cases. The condition affects newborns and significantly impacts their survival and long-term quality of life, making HLHS a critical focus for pediatric cardiology.

Longeveron Inc's Corporate Strategy and Funding Efforts Pave the Way for Cellular Therapies Advancements

Miami-based biotechnology company, Longeveron Inc. (NASDAQ: LGVN), recently issued a letter to shareholders highlighting its corporate strategy, clinical pipeline, and 2024 key priorities and goals. The company s CEO expressed optimism about the future, despite recording a significant cumulative net loss of $-20 million during the 12 months ending in the third quarter of 2023, resulting in a negative return on equity (ROE) of -147.9%.
Within the Major Pharmaceutical Preparations industry, Longeveron Inc. ranked relatively low in terms of return on equity compared to its peers, with 321 other companies surpassing its performance. Moreover, the company s total ranking in ROE deteriorated in the third quarter of 2023, falling from 3129 to 3485.

LGVN Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	6	22	7	21	37
Y / Y Equity Change	-74.07 %	224.68 %	-67.12 %	-45.26 %	-
Net Income in Millions	-23	-25	-22	-19	-17
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-400.07 %	-112.5 %	-329.49 %	-91.86 %	-45.51 %

Back to LGVN Management Effectiveness >> LGVN's 5 Years Annual ROE >> Compare LGVN ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
LGVN's' Return on Equity at Yahoo Finance
LGVN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for LGVN's Competitors
Subscribers only: Roe for Longeveron Inc 's Suppliers
Subscribers only: Return On Equity for LGVN's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-09-03T23:54:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.